# Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

> **NCT04659811** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nancy Ann Oberheim Bush, MD** · enrollment: 35 (actual)

## Conditions studied

- Grade I Meningioma, Adult
- Grade II Meningioma, Adult
- Grade III Meningioma, Adult
- Recurrent Meningioma

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Stereotactic Radiosurgery

## Key facts

- **NCT ID:** NCT04659811
- **Lead sponsor:** Nancy Ann Oberheim Bush, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-25
- **Primary completion:** 2027-03-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659811, "Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04659811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*